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Available online 31 March 2016Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising
therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and
characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this
platform by studying a hitherto neglected glucose- and appetite-regulating gut hormone, namely, oxyntomodulin.
Our results show that the secretion of oxyntomodulin in patients with type 2 diabetes is signiﬁcantly impaired,
and that its level is increased by more than 10-fold after gastric bypass surgery. Furthermore, we report that
oxyntomodulin is co-distributed and co-secreted with the insulin-stimulating and appetite-regulating
gut hormone glucagon-like peptide-1 (GLP-1), is inactivated by the same protease (dipeptidyl peptidase-4) as
GLP-1 and acts through its receptor. Thus, oxyntomodulinmay participate with GLP-1 in the regulation of glucose
metabolism and appetite in humans. In conclusion, thismass spectrometry-based platform is a powerful resource
for identifying and characterizing metabolically active low-abundance peptides.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Proteomics1. Introduction
Investigation of low-abundance peptides (peptides circulating
at the low picomolar range) has provided insights into human
physiology and pathophysiology. For example, the identiﬁcation of
the incretin hormone, glucagon-like peptide-1 (GLP-1), paved
the way to strategies for the treatment of diabetes and obesity
(Holst, 2013b; Sadry and Drucker, 2013; Wewer Albrechtsen et al.,
2014). Furthermore, low-abundance peptides derived from theSciences, Faculty of Health and
vej 3B, DK-2200 Copenhagen,
. This is an open access article undergastrointestinal tract, including GLP-1 (Supplementary Fig. 1), are
crucial mediators of the weight-reducing and antidiabetic actions
of bariatric surgery (Madsbad et al., 2014; Madsbad and Holst,
2014). Detection and characterization of low-abundance peptides
are, therefore, of major clinical interest (Bouillon et al., 2015;
Gillette and Carr, 2013a; Keshishian et al., 2007a; Lin et al., 2009;
Meng et al., 2011; Sadry and Drucker, 2013).
Therefore, we developed a streamlined, unbiasedmass spectrometry-
based platform for the characterization of low-abundance peptides
(Fig. 1.). Importantly, and in contrast to current targeted mass
spectrometry-based detection methods (Fonslow et al., 2011; Gillette
and Carr, 2013b; Keshishian et al., 2007b; Parker and Borchers, 2014;
Surinova et al., 2011) (e.g., the SISCAPA technology), this method
functions without prior immune-based fractionation/precipitation,
which makes this method unbiased and suitable for biomarker discov-
ery. The clinical applicability of the platformwas validated by detectingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A streamlined platform for detection of low-abundant peptides. This ﬁgure summarizes the key components in our mass-spectrometry based platform. Human blood or tissue
samples are puriﬁed using C18 materials and subsequently proteins are separated using high-performance liquid chromatography. Different proteases are then added to the 96 wells
to initiate protein digestion and formation of peptides. The samples are subsequently puriﬁed using C18 materials and subjected to liquid chromatography coupled to mass
spectrometry (LC–MS/MS) followed by data analysis using MaxQuant.
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hormone, oxyntomodulin.
2. Materials & methods
2.1. The perfused mouse intestine
Male C57BL/6J mice (10 weeks, purchased from Taconic, Denmark;
n = 4) were used for perfusion of the proximal intestine. Animals
were kept on a 12:12 h light–dark cycle with free access to standard
chow and water, and allowed to acclimatize for one week before use.
The animalswere anaesthetized by intraperitoneal injectionwith amix-
ture of ketamine/xylazine (Ketamine 90 mg/kg (Ketaminol Vet.; MSD
Animal Health, Madison, NJ, USA) + Xylazine 10 mg/kg (Rompun
Vet.; Bayer Animal Health, Leverkusen, Germany). The proximal small
intestine was perfused via a catheter (0.7 mm) in the aorta for inﬂow
of perfusion medium through the superior mesenteric artery at a ﬂow
rate of 2.2 ml/min as previously described. The stomach, kidneys,
spleen, colon and distal small intestine were tied off and removed to
prevent perfusion, thus only the proximal small intestine was perfused.
The venous efﬂuent was collected in 1 min periods via a catheter
(0.9 mm) inserted into the portal vein, now exclusively draining the
perfused segment. The intestinal lumen was perfused with saline at a
ﬂow rate of 0.04 ml/min. The perfusion medium (a modiﬁed Krebs
Ringer bicarbonate buffer containing, in addition, 0.1% bovine serum
albumin (Merck KGaA, Darmstadt, Germany), 5% Dextran T-70
(Dextran Products Limited, Scarborough, Canada), 3.5 mmol/l glucose,
and 5mmol/l of each of pyruvate, fumarate, and glutamate) was gassedwith a 95% O2/5% CO2 mixture to achieve pH 7.3–7.4 and maintained
at 37 °C during the experiment. After the intestinal perfusion was
established, the animals were exsanguinated and the intestine was
allowed to stabilise for approximately 30 min before the experiment
was started. Test substances (Neuromedin C (10 nmol/l) and KCl
(70 mmol/l) was infused through a sidearm with a syringe infusion
pump (0.11 ml/min) for 5–10 min followed by a resting period of
20 min. Chemicals were obtained from Sigma Aldrich (St. Louis, MO,
USA) unless otherwise stated. GLP-1 concentrations in venous efﬂuent
samples were measured, using a C-terminally directed (antiserum
(#89,390), which reacts fully with intact GLP-1 and its primary metab-
olite (Kuhre et al., 2014a; Kuhre et al., 2014b). Sample-size estimation
was based on a previous study (Svendsen et al., 2016).2.2. In vitro degradation of oxyntomodulin in human plasma
Blood from 10 healthy volunteers was collected into pre-chilled
EDTA tubes and centrifuged for 20 min at 2800 rpm at 4 °C. Plasma
was separated immediately, pooled and aliquoted in two portions.
Next, a DPP-4 inhibitor (valine pyrrolidide, a gift from Novo Nordisk
A/S, Bagsværd, Denmark; ﬁnal concentration 0.01 mmol/l) was added
to one portion of plasma and to one portion of assay buffer. Known
amounts of oxyntomodulin (corrected according to QAAA) were
added to plasmaportions and buffer portions to increase concentrations
by 0 (solvent only), 200 pmol/l. Subsequently, both plasma and buffer
portions were left at room temperature for 4 h andmeasured according
to protocol.
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Tissue was homogenized in 1% (v/v) triﬂuoroacetic acid (TFA)
(Cat. No. TS-28904, Thermo Fisher Scientiﬁc, MA, USA) with a
5 mm steel bead and a bead mill (TissueLyzer, Qiagen instruments
AG, Hombrechtikon, Switzerland) at 30 Hz for 2 × 2 min, left to stand
for 1 h at room temperature and then centrifuged (3.300 ×g, 10 min,
RT). Tissue extracts or pooled plasma (N = 9) were partially puriﬁed
using Sep-Pak pH-resistant tc18 cartridges (Cat. no. WAT036810, Wa-
ters, MA, USA) as described previously (Kuhre et al., 2014a; Kuhre
et al., 2014b), with peptides being eluted with 70% ethanol containing
0.1% TFA and dried under a gentle stream of compressed air overnight.
Liquid chromatography experiments: 1000 μL of reconstituted sam-
ples was injected in a rHPLC (Akta puriﬁer, Amersham Biosciences,
Vydac, Columbia, MD 21044, United States cat# 218tp5415, C18,
150 mm× 4.6 mm× 5 μM). The columnwas eluted with a linear gradi-
ent of 10–50% acetonitrile in 0.1% formic acid and ammonium acetate)
over 50 min and fractions were automatically sampled in 500 μL por-
tions, evaporated in a SpeedVac (Thermo Fisher Scientiﬁc, Odense,
Denmark) and stored at−80 °C until mass-spectrometry analysis or
ELISA measurement.
2.4. Mass-spectrometry based proteomic analysis
Protein pellets (HPLC fraction after evaporation) were resuspended
in digestion buffer with the proteases: LysC: 6/2 M urea/thiourea,
50 mM ammonium bicarbonate pH 7.5; Trypsin: 1.5/0.5 M urea/thio-
urea, 50 mM ammonium bicarbonate pH 7.5; and chymotrypsin: 0.3/
0.2 M urea/thiourea, 50 mM ammonium bicarbonate pH 7.5). Digestion
of ~0.2 μg proteinwas carried out with 1 μg of the respective enzyme. In
order to further increase the sequence coverage, partially cleaved
peptides were generated by digesting for 5, 10, 20, 40, 60, 120 and
720 min. Samples from all time points of a respective protease were
pooled and desalted on stage tips (Rappsilber et al., 2007).
LC–MS/MS: We ﬁrst separated peptides on a Thermo Scientiﬁc
EASY-nLC 1000 HPLC system (Thermo Fisher Scientiﬁc, Odense,
Denmark). Columns (75 μm inner diameter, 20 cm length) were in-
house packed with 1.9 μm C18 particles (Dr. Maisch GmbH, Germany).
Peptides were loaded in buffer A (0.5% formic acid) and separated
with a gradient from 5% to 60% buffer B (80% acetonitrile, 0.5% formic
acid) within 60 min at 250 nl/min. The column temperature was set
to 50 °C. The LC was directly coupled to a quadrupole Orbitrap mass
spectrometer (Scheltema et al., 2014) (Q Exactive HF, Thermo Fisher
Scientiﬁc) via a nanoelectrospray source. The Q Exactive was operated
in a data dependent mode. The survey scan range was set to 300 to
1650 m/z, with a resolution of 60,000 (Q Exactive HF) or 70,000
(Q Exactive). The up to the 10 most abundant isotope patterns with a
charge ≥ 2 were subjected to high collision fragmentation (Olsen et al.,
2007) at a normalized collision energy of 27 (Q Exactive HF) or 25
(Q Exactive) and a resolution of 15,000 (Q Exactive HF) or 17,500
(Q Exactive) at m/z 200. Dynamic exclusion of sequenced peptides
was set to 20s. Thresholds for ion injection time and ion target values
were set to 20 ms and 3*E6 for the survey scans and 120 ms (25 ms Q
Exactive HF) and 1E5 for the MS/MS scans, respectively. Data was
acquired using the Xcalibur software (Thermo Scientiﬁc).
Data analysis and statistics: We processed the raw data with
MaxQuant software (v 1.5.3.2) (4). We employed the Andromeda
search engine (Cox and Mann, 2008), which is integrated into
MaxQuant, to search MS/MS spectra against the human UniProtKB
FASTA database (59,345 forward entries; version of June 2012). Enzyme
speciﬁcity was set to semispeciﬁc. Peptides had to have a minimum
length of 7 amino acids to be considered for identiﬁcation. Carbamido-
methylation was set as ﬁxed modiﬁcation, acetylation (N-terminus),
deamidation and methionine oxidation were set as variable modiﬁca-
tions. A false discovery rate (FDR) cut-off of 1% was applied at the
peptide level. The cut-off score (delta score) for accepting individualMS/MS was 17. For bioinformatic analysis as well as visualization we
used the open PERSEUS environment, which is part of MaxQuant. For
several calculations and plots we also used the R framework. Identiﬁed
peptides were mapped to GCG. In order to display quantitative evidence
for overlapping peptides, intensities of identiﬁed peptideswere summed
and plotted per amino acid residue. All data is deposited for public access
using the PRIDE Archive.
2.5. Statistics
Speciﬁcity evaluation: For each assay, the concentrations measured
after addition of glucagon, oxyntomodulin or glicentin were plotted
against the calculated concentrations (after subtraction of plasma zero
values), and linear regression analyses were performed. The regression
coefﬁcient r2 shows the ﬁt of the line, and the slope of the ﬁtted linear
lines corresponds to the recovery in the tested assay (100% recovery
equates to full cross-reactivity, while a high regression coefﬁcient indi-
cates that ﬁndings were consistent and reproducible over the full tested
range); for the slopes of each line for each peptide and assay, P-values
were calculated for the null hypothesis: horizontal line. For the preci-
sion study, a one-way ANOVA for repeated measurements followed by
Bonferroni post hoc analysis was performed, comparing the spiked
samples and the baseline (non-spiked human plasma). For mouse gut
perfusion studies, the Pearson correlation coefﬁcient was used to assess
the co-secretion of oxyntomodulin and GLP-1. Clinical samples: Two-
way ANOVA with repeated measurement was used to determine
signiﬁcant differences between the oxyntomodulin and glicentin
concentration during meal challenges. Incremental area under the
curve (AUC) was calculated using the trapezoidal rule using baseline
as predictor. For testing of normality and homoscedasticity in datasets
we applied the Shapiro–Wilk test (swilk command) and drafted
residual plots. To test whether oxyntomodulin responses changed
after gastric bypass surgery, we performed a generalized regression
model (ANCOVA) with oxyntomodulin as dependent variable as
model 1 and glicentin asmodel 2, time from surgery being the indepen-
dent variable andGLP-2 concentrations as co-variates. P b 0.05was con-
sidered signiﬁcant. Calculations were made using GraphPad Prism
version 6.04 for Windows, GraphPad Software, La Jolla California USA,
www.graphpad.com and STAT14, Boston,MA, USA. Adobe CS6 software
suite (California, USA) was used for illustrations.
2.6. Study approval
Human samples are from studies by Hartmann (Hartmann et al.,
2013) (NCT01700686), Lund (NCT02475421) and Wewer Albrechtsen
(Wewer Albrechtsen et al., 2015). The studies were conducted accord-
ing to the latest revision of the Helsinki Declaration, and approved
by the Scientiﬁc-Ethical Committee of the Capital Region of Denmark
(H-2-2010-064) and by the Danish Data Protection Agency. Written
informed consent was received from participants prior to inclusion in
the studies. The animal studies were conducted in accordance with
international guidelines (National Institutes of Health publication no.
85–23, revised 1985, and Danish legislation governing animal experi-
mentation, 1987), and were carried out after permission had been
granted by the Animal Experiments Inspectorate, Ministry of Justice,
Denmark. For patient characteristic of the gastric bypass operated and
surgical procedures (Bonﬁls et al., 2015), see Supplementary material
& methods, and Supplementary Table 1.
3. Results
3.1. A streamlined mass spectrometry-based platform
We initially performed a number of pilot studies that included
optimization of blood and tissue handling for mass spectrometry
(see Materials & methods). To separate high-abundance proteins
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peptides of interest, we designed an isolation and fractionation ap-
proach: Plasma or tissue extracts were placed in a syringe containing
C18materials (SepPak) (Fig. 1), and the eluted peptides (low-abundance
peptides, see Supplementary Fig. 1) were subsequently fractionated by
high performance liquid chromatography (HPLC) using a gradient
optimized for detection of the low-abundance peptides (Fig. 1). The
platform thereby allows collection of fractions (N100) containing the
low-abundance peptides (the peptidome) for subsequent mass
spectrometry analysis. We employed proteases with different speciﬁc-
ities to maximize sequence coverage, and we used varying digestion
times to increase the number of unique peptides. Subsequently, the
low-abundance peptides were digested with speciﬁc proteases followed
by desalting on C18-ﬁlled tips (stage tips) (Aebersold and Mann, 2003;
Kulak et al., 2014; Rappsilber et al., 2007); they were then and analyzed
using state of the art mass spectrometry (Meissner et al., 2013;
Scheltema et al., 2014) that provided extreme sensitivity (~1 pg/ml).
Data were analyzed with the MaxQuant software suite, which enabled
reliable detection of the low-abundance peptides with false discovery
rates (FDR) below 1%. For validation of our platform, we spiked several
low-abundance peptides (the peptides shown in Supplementary Fig. 1.)
into PBS buffer and human plasma. Importantly, the low-abundanceFig. 2. Proteomic proﬁling of plasma from gastric bypass operated patients and human gut b
glicentin in human gut, plasma and from recombinant controls. B: Illustrates sequence cove
Evidence for coverage of the respective hormone is depicted as the summed peptide intens
replicates and 3 technical replicates are shown.peptides (Supplementary Fig. 2.) were detected independent of matrix
(buffer or plasma) in triplicate assays, with estimated recoveries of
(42 ± 8%) and coefﬁcients of variation b 90% and inter-assay variation
of less than 10% (for further details see Supplementary materials and
methods).
To demonstrate the clinical applicability of the mass spectrometry-
based platform, we analyzed plasma samples from gastric bypass
patients (N = 10), who were expected to have high levels of low-
abundance glucose- and appetite-regulating proglucagon-derived
peptides. We also analyzed gut extracts (n = 4) from the human
small intestine, which was also expected to have high levels.
3.2. Oxyntomodulin is secreted from the gut in response to glucose
Interestingly, subjecting human plasma and gut biopsies to our plat-
form provided complete sequence coverage for several proglucagon-
derived peptides (Fig. 2 and Supplementary Fig. 2.). False discovery
rate (FDR) levels were less than 1%, demonstrating that the platform
is robust even across tissue types (plasma and tissue biopsies). In addi-
tion, we validated the results from our immune-based oxyntomodulin
detection method using an FDA-based evaluation approach: epitope
mapping, HPLC fractionation, and ELISA evaluation (Supplementaryiopsies. A: Illustrates intensities of individual peptides identiﬁed of oxyntomodulin and
rage of oxyntomodulin and glicentin in human gut, plasma and recombinant controls.
ities per amino acid for all employed proteases (see Material & Methods). 10 biological
116 N.J. Wewer Albrechtsen et al. / EBioMedicine 7 (2016) 112–120Tables 2, 3 ,4, and 5, Supplementary Figs. 3. and 4). We hereby demon-
strate that the platform can be used to identify glucose- and appetite-
regulating hormones, such as oxyntomodulin, glicentin or GLP-1, in
human plasma and gut biopsies.Fig. 3.Oxyntomodulin responses are blunted in type 2 diabetic subjects and 10-fold elevated aft
and glicentin (black) in A: 10 healthy subjects (squares, full line) and 10 patients with type 2 d
incremental AUC of data presented inA; 18 obese non diabetic patients during a standardizedm
(E). F: tAUC calculated based on data from C,D,E. Data are mean± SEM. Asterisk (*) represents
multiple testing by Bonferroni post hoc analysis (F).Interestingly, our data suggest that oxyntomodulin is expressed
in the human small intestine and is secreted to the circulation after
stimulationwith nutrients, which is in contrast to the previous specula-
tion that it is a product made in circulation by the cleavage of otherer gastric bypass surgery. This ﬁgure illustrates the concentrations of oxyntomodulin (red)
iabetes (triangles, dotted line) during a standard OGTT challenge; B: Illustrates calculated
eal challenge before (C), 1month after gastric bypass (D) and 6months after gastric bypass
statistical signiﬁcant differences by a unpaired t-test (B) or one-way ANOVA correcting for
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investigate the secretory patterns of oxyntomodulin in obese subjects
before and after undergoing a gastric bypass operation. Furthermore,
to investigate if oxyntomodulin can be linked to the pleiotropic patho-
physiology of type 2 diabetes, we analyzed plasma (using the
extensively validated oxyntomodulin ELISA) during an oral glucose
load in subjects with type 2 diabetes and matched healthy controls.
3.3. Type 2 diabetes and gastric bypass surgery remodulate secretory
proﬁles of oxyntomodulin
Oxyntomodulin and glicentin levels increased (P b 0.01) from 12 to
20 pmol/l and 30 to 42 pmol/l, respectively, during an oral glucose
tolerance test (OGTT) in healthy subjects (Fig. 4A). Oxyntomodulin
and glicentin responses during the OGTT were (P b 0.01) lower in
patients with type 2 diabetes (P b 0.01) (Fig. 3, A and B): The incremen-
tal area under the curve (iAUC) for oxyntomodulin was 639 ±
69 min × pmol/l in healthy subjects and 248 ± 21 min × pmol/l in
patients with type 2 diabetes (P b 0.01), and the iAUC for glicentin
was 1296 ± 131 min × pmol/l in healthy subjects and 670 ±
71 min × pmol/l in patients with type 2 diabetes (P b 0.01). In obese
subjects, neither oxyntomodulin nor glicentin levels were signiﬁcantly
different compared to healthy subjects (P = 0.21) (Fig. 3C), but the
levels of both hormones were increased by more than 5-fold after
gastric bypass operations (Fig. 3, D and F, P = 0.001). The ratios
between oxyntomodulin and glicentin were relatively constant in all
groups, varying between 30 and 40%.
3.4. Oxyntomodulin and GLP-1 are co-distributed and co-secreted
We then investigated whether the secretion of oxyntomodulin and
GLP-1 are co-distributed and co-secreted. First, we investigated if the
enteroendocrine GLP-1-producing cells expressed oxyntomodulin.
Indeed, three GLP-1-producing cell lines expressed comparable
amounts of oxyntomodulin and GLP-1 (Fig. 4A). Then, analysis of
puriﬁed extracts from themouse gastrointestinal tract (Fig. 4B) demon-
strated that concentrations of oxyntomodulin increased (P ˂ 0.01) from
the proximal jejunum to the distal colon (23 ± 1 pmol/g to 73 ±
21 pmol/g) when compared to the duodenum. A similar pattern from
the proximal jejunum to the proximal colon was observed for GLP-1
(35 ± 6 pmol/g to 111 ± 12 pmol/g, Pearson correlation coefﬁcient of
0.921 P = 0.037)).
Finally, to study the (co-)secretion of oxyntomodulin and GLP-1, we
isolated and perfused the small intestine of four mice. Oxyntomodulin
secretion (Fig. 4C) increased (~9-fold, P ˂ 0.001) during infusion of
neuromedin C (7 ± 4 pmol/l to a peak of 62 ± 3 pmol/l) and KCl
(8 ± 2 pmol/l to peak of 64 ± 9 pmol/l), which were used to stimulate
enteroendocrine proglucagon-containing cell secretion (termed L-
cells). Importantly, these responses were in parallel with the secretion
of GLP-1 (~10-fold, P˂0.001, during infusion of neuromedin C (7 ±
2 pmol/l to peak at 78 ± 7 pmol/l) and KCl (10 ± 2 pmol/l to peak at
90 ± 19 pmol/l)). Oxyntomodulin and GLP-1 secretions were similar,
as illustrated by Fig. 4D and E, with a Pearson correlation coefﬁcient of
0.95 (P ˂ 0.001), suggesting that these low-abundance peptides detected
by the platform are co-distributed and are co-secreted.
3.5. Oxyntomodulin is degraded by the enzyme dipeptidyl-peptidase and
act through the GLP-1 receptor
It is well known that GLP-1 secreted from the gastrointestinal tract is
rapidly cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4), which
means that only ~8% of newly secreted GLP-1 reaches the pancreas in
its metabolically active form (Hansen et al., 1999; Hjollund et al.,
2011). DPP-4 inhibitors are now used to treat hyperglycemia in patients
with type 2 diabetes, as these drugs inhibit the degradation of GLP-1.
We hypothesized that oxyntomodulin are also degraded by DPP-4. Toaddress this, we incubated oxyntomodulin in human plasma (from 10
healthy subjects) with or without the addition of a DPP-4 inhibitor
(valine pyrrolidide). Inhibition of DPP-4 resulted in 21% higher
levels of oxyntomodulin in plasma (170 ± 11 versus 206 ± 15 pmol/l,
P = 0.011) but not in buffer, indicating a plasma-dependent effect
(Fig. 4F). DPP-4 inhibitors could therefore have a pleiotropic effect
not solely dependent on GLP-1. Finally, we tested if oxyntomodulin
mediates its effect through the GLP-1R. To do this, we treated GLP-1R
(a Gi-protein coupled receptor)-transfected cells (HEK293) with
oxyntomodulin and simultaneously blocked the GLP-1R (supplementa-
ry Fig. 5). GLP-1 and oxyntomodulin both exhibited robust stimulations
of cAMP levels (the down-stream signaling molecule of the receptor),
however, when we blocked the GLP-1R, the signal was signiﬁcantly
attenuated.
4. Discussion
We here demonstrate the clinical applicability of an unbiased mass
spectrometry-based platform in the pursuit of identifying low-
abundance regulatory peptides such as oxyntomodulin and GLP-1. The
platformwas used to identify glucose- and appetite-regulating peptides
both in circulation and in the gastrointestinal tract. In summary, we
show that oxyntomodulin is expressed in the human and mouse small
intestine, is co-distributed and co-secreted to the circulation with
GLP-1, and is degraded by the same enzyme as GLP-1, and we show
that both low-abundance peptides are elevated by more than 10-fold
after gastric bypass surgery and attenuated in subjects with type 2
diabetes. Oxyntomodulin may therefore act together with GLP-1 in reg-
ulating blood glucose and appetite in humans, which is consistent with
results of other studies that have injected exogenous oxyntomodulin
into humans (Bagger et al., 2015; Baldissera et al., 1988; Pocai, 2014;
Sandoval and D'Alessio, 2015; Schjoldager et al., 1988).
Our clinical observations are surprising and intriguing. First, it is well
established that secretion of GLP-1 is blunted in some subjectswith type
2 diabetes, and recent large-scale human studies suggest that the
decreased GLP-1 responses may contribute to the development of
type 2 diabetes (Calanna et al., 2013; Færch et al., 2015; Meier and
Nauck, 2010; Nauck et al., 2011). Our data demonstrate that levels of
oxyntomodulin are also attenuated in some subjects with type 2 diabe-
tes, suggesting that oxyntomodulin may contribute to the pleiotropic
pathophysiology of diabetes. However, our data do not demonstrate
causality of attenuated levels of oxyntomodulin and the development
of type 2 diabetes. Future studies may therefore investigate the molec-
ular background, of lower levels of oxyntomodulin, and ﬁnally assess
oxyntomodulin in a large cohort as done for GLP-1 (Færch et al., 2014).
In addition, exaggerated secretion of GLP-1 after gastric bypass
surgery has been suggested to contribute markedly to the antidiabetic
effect of this operation (Madsbad et al., 2014; Madsbad and Holst,
2014). We demonstrate that during a standardized meal test,
oxyntomodulin levels do increase, but by ~10-fold, supporting the
notion that the beneﬁcial effects of the gastric bypass intervention
may involve several glucose- and appetite-regulating gut hormones.
The mechanism(s) underlying the altered secretory proﬁles of
oxyntomodulin in gastric bypass operated subjects may include an
abnormal passage of nutrients to a site (1–2 m distal to the duodenum)
resulting in extreme exposure of nutrients to oxyntomodulin-
expressing cells (Holst, 2013a). and as a consequence expression of
oxyntomodulin in the gastrointestinal mucosa may increase (Rhee
et al., 2015). It may be speculated that it is these gastrointestinal
adaptation(s) that drives the dramatic changes in plasma levels of
oxyntomodulin. Interestingly, increased levels of oxyntomodulin
may be of importance appetite regulation, and in addtion glucose
homeostasis, and altered levels hereof could therefore have clinical
relevance supported by a human study demonstrating decreased
hunger and reduced food intake upon administration of oxyntomodulin
at supraphysiological levels (Cohen et al., 2003).
Fig. 4.Oxyntomodulin is co-distributed, co-secretedwith GLP-1 and act through same receptor. A: Concentrations of extractable oxyntomodulin (white boxes) and glicentin (black boxes)
normalized to protein content in GLUtag, NCI-H716 and STC-1 cells, the most frequently used cell models in incretin biology. B: Total GLP-1 tissue concentrations (black boxes) and
oxyntomodulin concentrations (red boxes) increase signiﬁcantly (P ˂ 0.001) along the gastrointestinal tract in mice (n = 10). C: Secretion of GLP-1 (black curve) and oxyntomodulin
(red curve) from perfused proximal small intestine (n = 4). Secretion was signiﬁcantly (P ˂ 0.05) increased by infusion of neuromedin C (10 mM) and KCL (70 mM). D: Averaged
levels of GLP-1 and oxyntomodulin during basal period compared to stimulation-period with either neuromedin C (grey) or KCl (black). Oxyntomodulin and GLP-1 secretion increased
in parallel during both neuromedin C and KCl stimulation. E: Correlation plot using data from C; the correlation coefﬁcient was 0.91 (R2). Data are illustrated as mean ± SEM.
* represent statistical signiﬁcant differences using a one-way ANOVA correcting for multiple testing by Bonferroni post hoc analysis (B) or a paired t-test (C). Differences between GLP-
1 and oxyntomodulin were not signiﬁcant. F: Levels of oxyntomodulin in buffer ±DPP-4 inhibition and human plasma ±DPP-4 inhibition. Measured levels of oxyntomodulin were
higher (P = 0.011) in plasma but not in buffer (P = 0.34) upon DPP-4 inhibition.
118 N.J. Wewer Albrechtsen et al. / EBioMedicine 7 (2016) 112–120The concentrations of proteins and peptides in plasma range from
picomolar to millimolar, a factor of 109, and this constitutes the main
challenge for analyzing low-abundance peptides in plasma (Mann
et al., 2013). Immune-based detection methods utilize the extremebinding energy of antibodies, which may have equilibrium constants
reaching values of 1012 l/mol, thereby giving thesemethods the potential
to detect very low concentrations. However, immune-based methods
often suffer from lack of speciﬁcity and interference, the so-calledmatrix
119N.J. Wewer Albrechtsen et al. / EBioMedicine 7 (2016) 112–120effects, i.e., sensitivity to other components in plasma, including a variety
of high-abundance plasma molecules or proteins (e.g., albumin and im-
munoglobulins); these can lead to unspeciﬁc interference in antibody–
antigen interaction and distort the results, particularly at the lower end
of the detection range (Kuhre et al., 2014a; Kuhre et al., 2014b). Impor-
tantly, the current mass spectrometry-based methods for detecting and
characterizing low-abundance peptides are immune-based and can
therefore only be used in a targeted manner (Lee et al., 2015), which is
undesirable for biomarker discovery.
In pursuit of improving the identiﬁcation and proﬁling of low-
abundance peptides, we developed a streamlined, mass spectrometry-
based platform for the characterization of low-abundance peptides in
blood and in tissue. As illustrated in Fig. 1, the developedpipeline involves
an isolation and fractionation approach for the identiﬁcation and quanti-
ﬁcation of peptides of interest using state of the art mass spectrometry.
Importantly, our platform does not employ immune-based fractionation
or precipitation and is therefore completely unbiased. We here provide
a method to identify an un-labeled, low-abundance peptide in human
plasma without prior immuno-based precipitation/puriﬁcation.
In summary, low-abundance peptides are key mediators of glucose
and appetite regulation, and the platform presented in the current
study may be a resource for identifying low-abundance peptides
in humans. We show that oxyntomodulin is co-distributed and co-
secreted with the insulin-stimulating and appetite-regulating gut
hormone GLP-1, is inactivated by the same protease (DPP-4) as GLP-1
and acts through its receptor therefore oxyntomodulin may be of
importance for regulating glucose homeostasis and appetite in humans.
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